Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AbbVie

Building Wealth with Spinoffs: How Adding These Gems Can Transform Your Portfolio

Spinoffs are value creating investment opportunities. You should be looking at them

The Unexpected Bad News For Novo's Ozempic In Biden's Drug Negotiations List

The Unexpected Bad News For Novo's Ozempic In Biden's Drug Negotiations List

Drugs from AbbVie, Bristol and Merck took slots on the list of drugs subject to price cuts. But the pharmaceutical stocks were unmoved.

Investors Business Daily

Big Pharma’s playbook for expensive meds

Big Pharma’s playbook for expensive meds

Here are just a few of the many examples of drug pricing practices that have driven consumers to demand change

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

How Revance Is Taking A Page Out Of AbbVie's Botox Playbook

Revance's frown-line injection, Daxxify, gained U.S. approval on Monday to treat an involuntary movement disorder, and RVNC stock rose.

Investors Business Daily

Are Pfizer (PFE) and AbbVie (ABBV) Good Value Buys for August?

The pharma industry is poised to witness long-term growth with the introduction of generic medicines and growing demand for personalized and targeted treatments. Hence, fundamentally strong pharma stock AbbVie (ABBV) might be worth buying. However, it might not be the right time to invest in Pfizer (PFE). Keep reading.

AbbVie’s Underperformance, Deere’s Catch-Up Potential, And Pioneer’s Earnings Awaited

AbbVie's underperformance, Jim Lebenthal sees Deere as a catch-up trade, and analysts await Pioneer's earnings report.

3 High-Paying Unusually Active Put Options to Sell for Extra Cash This Weekend

It’s the last day of the trading week, so investors are looking for extra spending money for the weekend ahead. Here are three unusually active put options to sell: high-paying and worthwhile long-term holds.

inkl

Read news from The Economist, FT, and more,
with one subscription

AbbVie Results Fall But The Drop Isn't As Severe As Expected; Shares Climb

AbbVie Results Fall But The Drop Isn't As Severe As Expected; Shares Climb

Drug maker AbbVie reported second-quarter profit and sales that fell from a year earlier but topped expectations. AbbVie stock rose.

Investors Business Daily

Humira, the world’s top-selling drug, faces an upcoming test from low cost alternatives

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor.

Tribune News Service

Cheaper competition for Humira is hitting the market, but savings will depend on your insurance

Cheaper competition for Humira is hitting the market, but savings will depend on your insurance

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July

The Independent UK

3 Dependable Dividend Stocks to Consider in the Second Half Of 2023

3 Dependable Dividend Stocks to Consider in the Second Half Of 2023

These 3 dividend stocks have uninterruptedly paid and raised their dividends for years. Further, these stocks have outperformed the broader markets, and Wall Street analysts have a favorable outlook on them.

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree

Big Pharma has a problem, and buying up biotech companies helps solve it. But the FTC has its own ideas about industry mergers. Here's where things stand.

Investors Business Daily

Best Retirement Stocks for Income Investors in the Golden Years

Best Retirement Stocks for Income Investors in the Golden Years

The best retirement stocks ideally have attractive dividends that can be sustained. This can lead to steady income and long-term value for retirees.

Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review

Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review

The stock market rally went to "under pressure" amid big earnings moves and revived banking fears, but the major indexes ultimately closed tightly again.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?

Industry analysts warn that a groundbreaking change in how Medicare buys drugs threatens industry growth, profits — and maybe patient care.

Investors Business Daily

AbbVie's Humira Downfall Is Swift As Biosimilars Hammer Away At Sales

AbbVie stock crumbled Thursday after the first biosimilar to launch in the U.S. hammered away at Humira's legendary sales.

Investors Business Daily

Dow Jones Futures Rise: Meta Soars, Drug Giants Climb, Specialty Chip Plays Dive

Futures: Meta Platforms boomed on earnings, but megacap techs can't hide broad market rally weakness. First Republic dived again.

Investors Business Daily

AbbVie Stock Shows Improved Relative Price Strength

AbbVie shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Get all your
news in one place.

100’s of premium titles.
One news app.

AbbVie’s Call Action Suggests It Might Just Be a Buy

Barchart.com’s Unusual Options Activity on Wednesday had 18 AbbVie call options in the Top 100. Not everyone believes it’s an excellent time to buy ABBV stock. Yesterday’s options market says otherwise.

Reskilling and financial well-being top HR’s talent strategy list amid economic downturn

Fortune 500 HR execs share how they’re recession-proofing their talent strategy. Hint: Financial wellness benefits and reskilling.

How Fortune 500 companies are supporting employees amid financial instability

Financial wellness benefits have become popular as employers focus on retention.

Chicago Tribune

Federal government to penalize AbbVie over the price of its blockbuster drug Humira

North Chicago-based drugmaker AbbVie must pay back Medicare for raising the price of its blockbuster drug Humira too quickly, the federal government said Wednesday.

Investors Business Daily

AbbVie Stock Shows Rising Relative Strength, Still Has More To Go

A Relative Strength Rating upgrade for AbbVie shows improving technical performance. Will it continue?

Investors Business Daily

AbbVie's Humira: The Downfall Won't Be As 'Draconian' As Initially Expected

AbbVie stock won at least one upgrade Friday after issuing long-awaited guidance for Humira for the first year it faces new competition.

Investors Business Daily

AbbVie Rises As Lagging Profit Outlook Better Than Feared In Humira Battle Year

AbbVie stock inched higher Thursday after the company reported mixed earnings and issued a light profit outlook.

People

Christopher Raymond

Alex Oshmyansky

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Intel Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Autoimmune Disease

Places

290,393 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play